Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
ARDX is in the long-term down -86% below S&P in 4 years.
Description: Ardelyx, Inc. discovers, develops, and commercializes non-systemic small molecule therapeutics for the gastrointestinal tract to treat cardio-renal and metabolic diseases. Its lead product candidate is Tenapanor, a small molecule, orally administered inhibitor of NHE3, which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. The company also evaluates small molecule NaP2b inhibitors for the treatment of hyperphosphatemia in end stage renal disease. In addition, its other discovery and lead development programs consist of RDX009, RDX013, and RDX020 programs that are in research phase focusing on cardio-renal and metabolic diseases. It has a collaboration partnership agreement with AstraZeneca AB for the development and commercialization of tenapanor. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was founded in 2007 an
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||-2.73||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-35.61%||Sales Growth - Q/Q||-7.19%||P/E||-1.59|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-3.46%||ROE||-6.28%||ROI|
|Current Ratio||5.12||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.34|
|Gross Margin||Operating Margin||-15.85%||Net Profit Margin||-12.59%||Dividend Payout Ratio|
|Cash From Financing Activities||300 K||Cash From Investing Activities||-1.05 M||Cash From Operating Activities||-8.21 M||Gross Profit|
|Net Profit||-3.5 M||Operating Profit||-3.49 M||Total Assets||105.4 M||Total Current Assets||101.91 M|
|Total Current Liabilities||19.91 M||Total Debt||Total Liabilities||47.4 M||Total Revenue||5.88 M|
|High 52 week||7.9||Low 52 week||1.66||Last close||2.23||Last change||-4.29%|
|RSI||69.29||Average true range||0.19||Beta||1.5||Volume||61.04 K|
|Simple moving average 20 days||10.4%||Simple moving average 50 days||-8.8%||Simple moving average 200 days||-41.66%|
|Performance Week||-7.08%||Performance Month||3.72%||Performance Quart||-39.89%||Performance Half||-52.04%|
|Performance Year||-68.59%||Performance Year-to-date||24.58%||Volatility daily||5.5%||Volatility weekly||12.3%|
|Volatility monthly||25.21%||Volatility yearly||87.35%||Relative Volume||187.64%||Average Volume||352.07 K|
|New High||New Low|
2019-09-13 12:29:27 | A Look At Benzinga Pro's Most-Searched Tickers For September 13, 2019
2019-09-13 11:08:03 | Ardelyx Gets FDA Approval for Ibsrela As IBS-C Treatment
2019-09-13 08:24:12 | Ardelyx ARDX in Focus: Stock Moves 8.3% Higher
2019-09-11 17:47:02 | East Bay company eyes first drug approval after decade-long journey
2019-09-04 16:42:04 | Biotech Stock On The Radar: Ardelyx Gears Up For FDA Decision Day
2019-09-04 12:07:41 | A Look At Benzinga Pro's Most-Searched Tickers For September 4, 2019
2019-09-04 12:00:00 | Why Ardelyx Shares Are Sinking Today
2019-09-04 10:31:02 | Ardelyx ARDX Gains on Tenapanor's Success in Pivotal Study
2019-09-04 10:02:02 | Biotech Stock Roundup: REGN Wins Against AMGN, VRTX to Acquire Semma & More
2019-09-04 07:08:03 | The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books
2019-09-03 10:56:00 | Why Ardelyx Is Soaring Today
2019-09-03 08:00:00 | Ardelyx Announces Positive Results from the Pivotal Phase 3 AMPLIFY Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment
2019-08-21 13:06:52 | How Many Ardelyx, Inc. NASDAQ:ARDX Shares Do Institutions Own?
2019-08-19 06:00:00 | 5 Biggest New Drug Approvals Potentially on the Way in 2019
2019-08-09 09:25:01 | Ardelyx ARDX Reports Q2 Loss, Misses Revenue Estimates
2019-08-09 08:00:00 | Ardelyx Reports Second Quarter 2019 Financial Results and Recent Business Highlights
2019-07-30 10:38:02 | Ardelyx ARDX May Report Negative Earnings: Know the Trend Ahead of Q2 Release
2019-07-09 13:49:01 | Does The Ardelyx, Inc. NASDAQ:ARDX Share Price Tend To Follow The Market?
2019-06-25 20:33:43 | Is Ardelyx Inc ARDX A Good Stock To Buy?
2019-05-30 09:00:00 | Ardelyx to Present at the Jefferies 2019 Global Healthcare Conference
2019-05-16 12:56:15 | Why Ardelyx, Inc.'s NASDAQ:ARDX CEO Pay Matters To You
2019-05-07 18:45:10 | Ardelyx ARDX Reports Q1 Loss, Misses Revenue Estimates
2019-05-07 17:34:27 | Ardelyx: 1Q Earnings Snapshot
2019-05-07 16:02:00 | Ardelyx Reports First Quarter 2019 Financial Results and Recent Business Highlights
2019-05-07 10:30:02 | Ardelyx ARDX Expected to Beat Earnings Estimates: Should You Buy?
2019-05-06 09:55:01 | What's in the Cards for Axon Enterprise AAXN Earnings?
2019-03-06 16:05:00 | Ardelyx Reports Fourth Quarter 2018 Financial Results and Recent Highlights
2019-03-01 14:54:24 | An Examination Of Ardelyx, Inc. NASDAQ:ARDX
2019-02-21 08:00:00 | Ardelyx to Participate in Leerink Partners 8th Annual Global Healthcare Conference
2019-02-12 08:25:00 | Factors of Influence in 2019, Key Indicators and Opportunity within Park Hotels & Resorts, Planet Fitness, Aevi Genomic Medicine, Ardelyx, AMERISAFE, and inTest — New Research Emphasizes Economic Growth
2019-01-18 09:20:26 | Ardelyx, Inc. NASDAQ:ARDX Is Trading At A 28.78% Discount
2018-12-18 02:50:44 | Ardelyx Inc ARDX: Are Hedge Funds Right About This Stock?
2018-11-26 14:26:07 | What Type Of Shareholder Owns Ardelyx Inc’s NASDAQ:ARDX?
2018-11-07 18:12:34 | Ardelyx: 3Q Earnings Snapshot
2018-11-07 16:05:00 | Ardelyx Reports Third Quarter 2018 Financial Results and Recent Highlights
2018-10-16 07:50:00 | Analysis: Positioning to Benefit within Ardelyx, AXT, TG Therapeutics, MarineMax, Oclaro, and BioCryst Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
2018-09-18 08:19:01 | How Does Investing In Ardelyx Inc NASDAQ:ARDX Impact Your Portfolio?